ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

10 links0 made here, not in the record17 judgments2 judges (the rules as one: Rule based)0 record changes seen
Claude Opus 5.5Rule based
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT07383441Adding Biotherapy orPlacebo to StandardTreatment for AdvancedKidney CancerSWOG Cancer Research NetworkPhase 3 · recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›No new version seen since tracking began Sep 25, 2026.CONDITIONSClear-cell metastatic renal…The registry's MeSH filing›As of now · Rule based · Main conditionMain conditionCarcinoma, Renal CellThe registry's MeSH filing›No judgment recorded. Shown as the registry files it.DRUGSAxitinibIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundCabozantinibIntervention entry›Nov 2 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partnerClostridium butyricum miyai…Entry “Clostridium butyricum CBM 588 …›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedIpilimumabIntervention entry›Nov 2 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partnerLenvatinibIntervention entry›Nov 2 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partnerNivolumabIntervention entry›Nov 2 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partnerNivolumab and Recombinant H…Intervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundPembrolizumabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackground

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Axitinib

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Axitinib”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Background
Background · 2

All judgments on this study

WhenLinkJudgeDecisionState
Nov 2AxitinibClaude Opus 5.5BackgroundCurrent
Nov 2CabozantinibClaude Opus 5.5Background · partnerCurrent
Nov 2Clostridium butyricum miyairi 588 strainClaude Opus 5.5TestedCurrent
Nov 2IpilimumabClaude Opus 5.5Background · partnerCurrent
Nov 2LenvatinibClaude Opus 5.5Background · partnerCurrent
Nov 2NivolumabClaude Opus 5.5Background · partnerCurrent
Nov 2Nivolumab and Recombinant Human HyaluronidaseClaude Opus 5.5BackgroundCurrent
Nov 2PembrolizumabClaude Opus 5.5BackgroundCurrent
Nov 18AxitinibRule based · role ruleBackgroundAgrees
Nov 18CabozantinibRule based · role ruleBackgroundAgrees
Nov 18Clostridium butyricum miyairi 588 strainRule based · role ruleTestedAgrees
Nov 18IpilimumabRule based · role ruleBackgroundAgrees
Nov 18LenvatinibRule based · role ruleBackgroundAgrees
Nov 18NivolumabRule based · role ruleBackgroundAgrees
Nov 18Nivolumab and Recombinant Human HyaluronidaseRule based · role ruleBackgroundAgrees
Nov 18PembrolizumabRule based · role ruleBackgroundAgrees
As of nowClear-cell metastatic renal cell carcinomaRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.